A home-based healthcare provider raises the low end of its 2026 revenue forecast to $316 million.
Viemed Healthcare (VMD) reported Q3 2026 revenue of $80.7M, up 12.2% YoY, and raised its 2026 revenue forecast low end to $316M. Net income rose 32% YoY to $4.6M, with adjusted EBITDA at $17.1M. The company also updated its full-year guidance, narrowing Adjusted EBITDA and lowering net capital expenditure outlook.
How this was made
The 30-second read
Why it matters
The upward revision of revenue guidance and record quarterly performance are likely to attract investor interest and could drive the stock higher in the near term.
Market read
First‑report earnings and guidance update for a small‑cap healthcare company; potential catalyst for price movement.
What to watch
Potential regulatory changes and payer reimbursement pressure could curb future growth.
Background
Viemed Healthcare, a NASDAQ‑listed home‑based health services provider, released its Q3 2026 results and updated full‑year guidance.
Ticker impact
Viemed raised the low end of its 2026 revenue guidance to $316M and reported record Q3 revenue of $80.7M.
likely upside as investors price in higher revenue outlook
The upward revision of revenue guidance and record quarterly results suggest improved operating performance, which typically supports a price rally.
Market effects
Home‑based healthcare providers may benefit from perceived demand growth.
U.S. healthcare stocks could see modest buying pressure.
Limited to U.S. small‑cap healthcare sector.
Counterpoint
Guidance may be optimistic given higher capital intensity and reimbursement risks.
Key entities
- companyViemed Healthcare, Inc.
NASDAQ:VMD, provider of home‑based healthcare solutions.
- executiveCasey Hoyt
CEO of Viemed who commented on the results.




